HDL-Therapy – Therapeutic approaches to correction of High-density lipoproteins dysfunction

  • D. D. Sviridov Institute of General Pathology and Pathophysiology, Moscow, Russian Federation; Institute for Atherosclerosis Research, Skolkovo, Moscow, Russian Federation
  • V. P. Karagodin Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow, Russian Federation
  • V. A. Orekhova Institute of General Pathology and Pathophysiology, Moscow, Russian Federation
  • A. A. Melnichenko Institute of General Pathology and Pathophysiology, Moscow, Russian Federation
  • A. N. Orekhov Institute of General Pathology and Pathophysiology, Moscow, Russian Federation; Institute for Atherosclerosis Research, Skolkovo, Moscow, Russian Federation
Keywords: atherosclerosis, high-density lipoproteins, cholesterol, therapy

Abstract

The authors describe in this review the promising therapeutic approaches for raising HDL levels in blood for inhibition of atheroscletosis. The mechanisms of action and efficacy of the most commonly used and emergtng drugs for this purpose are discussed. It is assumed that the development of new opportunities that stimulate formation of these lipoprotein fractions can reduce the severity of cardiovascutar pathology. There is a growing attention to the ability to characterize the functionality of HDL caused by their heterogeneity. These data suggest the most likely use of more than one therapeutic approach to successfully elevate the content of HDL.

Published
2023-05-31
How to Cite
Sviridov, D. D., Karagodin, V. P., Orekhova, V. A., Melnichenko, A. A., & Orekhov, A. N. (2023). HDL-Therapy – Therapeutic approaches to correction of High-density lipoproteins dysfunction. Patogenez (Pathogenesis), 10(2), 4-18. Retrieved from https://pathogenesis.pro/index.php/pathogenesis/article/view/705